GlassScriptPhysician profile
Vinaya Koduri
NPI 1043326887
$3,434.91
in general payments reported to CMS, 2019-2025
31 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $16.79 · 2021: $406 · 2022: $700 · 2023: $621 · 2024: $700 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,746.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $568.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $499.65 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.71 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $260.58 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $232.96 | 2023-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $184.17 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $183.17 | 2019-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $170.93 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $148.90 | 2019-2023 | Eliquis |
| Abbvie INC. | $124.91 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $110.81 | 2019-2024 | |
| Abbott Laboratories | $77.01 | 2021-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $74.26 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.99 | 2019-2025 | Xifaxan, Trulance |
| Fresenius Kabi USA, LLC | $39.34 | 2023 | Idacio |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $37.82 | 2019 | |
| Ibsa Pharma INC. | $34.25 | 2023 | Tirosint, Licart |
| Xeris Pharmaceuticals, INC. | $33.85 | 2022-2023 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $31.72 | 2021-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $30.47 | 2019-2023 | |
| Amarin Pharma, INC. | $27.00 | 2019 | |
| Scilex Pharmaceuticals INC. | $25.00 | 2019 | |
| Dexcom, INC. | $22.24 | 2023 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $18.74 | 2024 | Voquezna |
| Organon LLC | $17.90 | 2024 | |
| Ucb, INC. | $17.59 | 2019 | |
| Valeritas, INC. | $17.11 | 2019 | |
| Astellas Pharma US INC | $17.09 | 2019 | |
| Genentech USA, INC. | $14.24 | 2021 | |
| Sanofi Pasteur INC. | $13.65 | 2023 | |
| Nevro Corp. | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinaya Koduri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.